Mass Medical Angels

Mass Medical Angels is a venture capital firm based in Brookline, Massachusetts, founded in 2007. The firm specializes in seed and early-stage investments within the life sciences and healthcare sectors, focusing on medical devices, therapeutics, diagnostics, health services, health information technologies, and research-related tools. Recognizing the challenges early-stage companies face in securing initial funding, particularly in the Boston area, Mass Medical Angels aims to provide financial support and mentorship to foster innovation in the medical field. Their typical investment amounts range from $2 million to $7.5 million, with the goal of achieving favorable returns while enhancing clinical innovation in the community.

Carl Berke

Co-Founder and Managing Director

25 past transactions

Astrocyte Pharma

Series A in 2021
Astrocyte Pharmaceuticals Inc. is a privately held drug development company based in Cambridge, Massachusetts, focused on creating neuroprotection therapies for various brain injuries, including traumatic brain injuries (TBI), concussions, acute ischemic stroke, and neurodegenerative disorders like Alzheimer’s disease. Incorporated in 2014, the company is advancing its lead product, AST-004, a novel small molecule designed for acute administration. This therapy aims to protect and repair damaged neurons by selectively stimulating astrocytes, a type of brain cell crucial for neuronal health. Astrocyte Pharmaceuticals is dedicated to demonstrating the neuroprotective benefits of its approach and improving outcomes for patients suffering from brain injuries.

Coviu

Venture Round in 2020
Coviu Global Pty Ltd provides telehealth tool to practitioners to help deliver video healthcare consultations to patients. It also offers practice management systems for patient record management. Its tool provides facilities, such as waiting area, customized clinics, dashboard, clinical governance, and white labelling. The company is incorporated in 2015 and is based in Sydney, Australia.

Capillary Biomedical

Seed Round in 2018
Capillary Biomedical is a medical device startup developing technologies for diabetes management. They aim to dramatically simplify glucose monitoring and insulin delivery, reducing the burden on both patients and the overall healthcare system. The company is based in Irvine, CA and is a spin-out of the Artificial Pancreas Center at the Sidney Kimmel Medical College of Thomas Jefferson University in Philadelphia, PA.

Lantos

Venture Round in 2018
Lantos Technologies, Inc. specializes in 3D digital ear scanning technology that facilitates the creation of personalized in-ear devices. The company offers the AURA 3D ear scanning system, which is utilized for designing in-ear headphones, musicians' monitors, hearing aids, and noise protection solutions. Lantos Technologies is recognized for having the only FDA-cleared 3D ear scanning system, which enhances the quality and efficiency of custom ear products by capturing detailed measurements from the outer ear to the second bend of the ear canal. Founded in 2009 and based in Derry, New Hampshire, the company was formerly known as Lantos 2.0 Inc. before rebranding in December 2020.

Astrocyte Pharma

Seed Round in 2017
Astrocyte Pharmaceuticals Inc. is a privately held drug development company based in Cambridge, Massachusetts, focused on creating neuroprotection therapies for various brain injuries, including traumatic brain injuries (TBI), concussions, acute ischemic stroke, and neurodegenerative disorders like Alzheimer’s disease. Incorporated in 2014, the company is advancing its lead product, AST-004, a novel small molecule designed for acute administration. This therapy aims to protect and repair damaged neurons by selectively stimulating astrocytes, a type of brain cell crucial for neuronal health. Astrocyte Pharmaceuticals is dedicated to demonstrating the neuroprotective benefits of its approach and improving outcomes for patients suffering from brain injuries.

Sentieon

Series A in 2017
Sentieon, Inc. is a biotechnology company founded in 2014 and headquartered in Mountain View, California, specializing in cloud-based bioinformatics solutions for the life sciences and clinical markets. The company develops a suite of bioinformatics tools designed for the efficient processing of genomics data, focusing on high accuracy and computational efficiency. Key products include Sentieon DNAseq, which facilitates germline DNA analysis, and Sentieon TNseq, used for detecting somatic variants in tumor-normal samples. Sentieon's software solutions are characterized by their scalability, deployability, and upgradability, allowing them to adapt to various user needs. The company's advanced algorithms and robust software implementation ensure rapid turnaround times and consistent results, benefiting scientists, clinicians, and patients by enhancing precision in genomic data analysis.

Sentien

Series A in 2017
Sentien Biotechnologies, Inc. develops proprietary cell compositions and GMP manufacturing methods to advance combination products that unlock the potential of cell therapy. It provides the Sentinel, a device that actively treats patients during a dialysis dose by supplementing patient blood with MSC-derived secretions, a combinational mixture of natural anti-inflammatory and trophic molecules that can attenuate the immune dysfunction of acute renal failure while promoting a tissue repairing response. The company was founded in 2008 and is headquartered in Medford, Massachusetts.

InfoBionic

Series B in 2014
InfoBionic, Inc. is a healthcare technology company based in Massachusetts, founded in 2011. It specializes in remote patient monitoring through its MoMe™ platform, which is a cloud-based service designed to enhance the efficiency of cardiac diagnostic services. The MoMe System focuses on cardiac arrhythmia detection, allowing healthcare providers to monitor patients' heart health continuously by streaming electrocardiogram, respiration, and motion data to the cloud for real-time analysis. This technology aims to improve clinical efficiency and patient care by providing physicians with anytime, anywhere access to critical patient data, ultimately facilitating better detection and treatment of cardiac complications.

Siamab Therapeutics

Series B in 2014
Siamab Therapeutics is a biopharmaceutical company that develops therapies targeting abnormal carbohydrates found only on cancer cells. It has developed a platform of technologies that enables the discovery and development of anti-TACA therapeutic antibodies. The company’s core technologies were licensed from the laboratory of Ajit Varki, a professional in glycobiology and sialic-acid biochemistry. It has brought together a team of scientists and advisors in oncology, glycoimmunology, and antibody engineering to support its anti-TACA antibody discovery and development programs. Siamab Therapeutics was founded in 2006 and is headquartered in Newton, M.A.

Siamab Therapeutics

Series B in 2013
Siamab Therapeutics is a biopharmaceutical company that develops therapies targeting abnormal carbohydrates found only on cancer cells. It has developed a platform of technologies that enables the discovery and development of anti-TACA therapeutic antibodies. The company’s core technologies were licensed from the laboratory of Ajit Varki, a professional in glycobiology and sialic-acid biochemistry. It has brought together a team of scientists and advisors in oncology, glycoimmunology, and antibody engineering to support its anti-TACA antibody discovery and development programs. Siamab Therapeutics was founded in 2006 and is headquartered in Newton, M.A.

Avaxia Biologics

Series B in 2013
Avaxia Biologics, Inc. operates as a biopharmaceutical company that develops oral antibody therapeutics. It offers gastrointestinal diseases, such as inflammatory bowel diseases, celiac disease, necrotizing enterocolitis, radiation syndrome, oral mucositis, and diabetes and obesity. Avaxia Biologics, Inc. has a strategic collaboration with Courtagen Life Sciences, Inc. The company was founded in 2005 and is based in Lexington, Massachusetts. Avaxia Biologics, Inc. operates as a subsidiary of Circle33 LLC.

Avaxia Biologics

Series B in 2012
Avaxia Biologics, Inc. operates as a biopharmaceutical company that develops oral antibody therapeutics. It offers gastrointestinal diseases, such as inflammatory bowel diseases, celiac disease, necrotizing enterocolitis, radiation syndrome, oral mucositis, and diabetes and obesity. Avaxia Biologics, Inc. has a strategic collaboration with Courtagen Life Sciences, Inc. The company was founded in 2005 and is based in Lexington, Massachusetts. Avaxia Biologics, Inc. operates as a subsidiary of Circle33 LLC.

Diffinity Genomics

Series B in 2012
Diffinity Genomics, Inc. is a biotechnology company based in West Henrietta, New York, that specializes in developing single-use disposable products for nucleic acid isolation and analysis in the life sciences sector. Founded in 2005, the company offers a range of products, including RapidTip, a functional pipette tip designed for purifying polymerase chain reaction (PCR) amplicons, and various other RapidTip variants that facilitate DNA purification for different applications, such as Sanger sequencing and downstream reactions. Diffinity Genomics serves a diverse clientele, including life science professionals engaged in DNA analysis, as well as industrial and academic research laboratories around the globe. The company utilizes proprietary technology to streamline nucleic acid purification processes, thereby enhancing efficiency in medical, industrial, and research settings.

Avaxia Biologics

Series A in 2012
Avaxia Biologics, Inc. operates as a biopharmaceutical company that develops oral antibody therapeutics. It offers gastrointestinal diseases, such as inflammatory bowel diseases, celiac disease, necrotizing enterocolitis, radiation syndrome, oral mucositis, and diabetes and obesity. Avaxia Biologics, Inc. has a strategic collaboration with Courtagen Life Sciences, Inc. The company was founded in 2005 and is based in Lexington, Massachusetts. Avaxia Biologics, Inc. operates as a subsidiary of Circle33 LLC.

lifeIMAGE

Series B in 2011
LifeIMAGE is an online network that enables individuals to exchange medical images. LifeIMAGE is interoperable with the hospital EMR to provide integrated access to medical images, from anywhere. Clinicians can exchange medical images with patients and providers, anywhere. It was founded in 2008 and headquartered in Newton, Massachusetts.

Lantos

Venture Round in 2011
Lantos Technologies, Inc. specializes in 3D digital ear scanning technology that facilitates the creation of personalized in-ear devices. The company offers the AURA 3D ear scanning system, which is utilized for designing in-ear headphones, musicians' monitors, hearing aids, and noise protection solutions. Lantos Technologies is recognized for having the only FDA-cleared 3D ear scanning system, which enhances the quality and efficiency of custom ear products by capturing detailed measurements from the outer ear to the second bend of the ear canal. Founded in 2009 and based in Derry, New Hampshire, the company was formerly known as Lantos 2.0 Inc. before rebranding in December 2020.

Annovation BioPharma

Venture Round in 2011
Annovation BioPharma develops pharmaceutical products in the field of anesthesia, sedation, and sleep. The company was incorporated in 2009 and is based in Wayland, Massachusetts.

MoMelan Technologies

Series A in 2011
MoMelan Technologies, Inc. operates as a developer of a device to treat skin disorders by expanding the surface area of skin grafts. The company was incorporated in 2009 and is based in Cambridge, Massachusetts. MoMelan Technologies, Inc. operates as a subsidiary of Acelity L.P. Inc.

Bliss Health

Seed Round in 2011
Bliss Health offers care management services through a network of integrated medical, nursing, and home care services.

Polytouch Medical

Seed Round in 2010
Polytouch Medical focuses on advancing minimally invasive surgery by developing innovative solutions for laparoscopic procedures, particularly in hernia repair. The company specializes in hernia mesh placement technologies, with its flagship product, PatchAssist, designed to enhance the deployment and positioning of mesh during surgery. This technology primarily targets ventral hernias, enabling patients to initiate treatment more swiftly and improving the chances of successful outcomes. Polytouch Medical collaborates closely with physicians to ensure that their products effectively address clinical needs, while a dedicated team of employees and medical advisors work together to transform innovative ideas into practical solutions.

Lantos

Venture Round in 2010
Lantos Technologies, Inc. specializes in 3D digital ear scanning technology that facilitates the creation of personalized in-ear devices. The company offers the AURA 3D ear scanning system, which is utilized for designing in-ear headphones, musicians' monitors, hearing aids, and noise protection solutions. Lantos Technologies is recognized for having the only FDA-cleared 3D ear scanning system, which enhances the quality and efficiency of custom ear products by capturing detailed measurements from the outer ear to the second bend of the ear canal. Founded in 2009 and based in Derry, New Hampshire, the company was formerly known as Lantos 2.0 Inc. before rebranding in December 2020.

lifeIMAGE

Series A in 2009
LifeIMAGE is an online network that enables individuals to exchange medical images. LifeIMAGE is interoperable with the hospital EMR to provide integrated access to medical images, from anywhere. Clinicians can exchange medical images with patients and providers, anywhere. It was founded in 2008 and headquartered in Newton, Massachusetts.

Daktari Diagnostics

Series A in 2009
Daktari Diagnostics, Inc., a healthcare solutions company, develops and provides portable point-of-care diagnostic platforms for disease management Worldwide. It offers Daktari Virology, a platform for HCV and HIV detection; Daktari InSight, a data management service that connects Daktari’s systems to its customers; and Daktari Sickle Cell, a solution that provides tests to identify infants with sickle cell disease from a drop of blood. The company was founded in 2008 and is based in Cambridge, Massachusetts.

lifeIMAGE

Series A in 2009
LifeIMAGE is an online network that enables individuals to exchange medical images. LifeIMAGE is interoperable with the hospital EMR to provide integrated access to medical images, from anywhere. Clinicians can exchange medical images with patients and providers, anywhere. It was founded in 2008 and headquartered in Newton, Massachusetts.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.